BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30300823)

  • 1. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function.
    Maimaitili Y; Inase A; Miyata Y; Kitao A; Mizutani Y; Kakiuchi S; Shimono Y; Saito Y; Sonoki T; Minami H; Matsuoka H
    Leuk Res; 2018 Nov; 74():68-74. PubMed ID: 30300823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.
    Mizutani Y; Inase A; Maimaitili Y; Miyata Y; Kitao A; Matsumoto H; Kawaguchi K; Higashime A; Goto H; Kurata K; Yakushijin K; Minami H; Matsuoka H
    Int J Hematol; 2019 Oct; 110(4):490-499. PubMed ID: 31286402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy.
    Seo SU; Woo SM; Lee HS; Kim SH; Min KJ; Kwon TK
    Oncogene; 2018 Sep; 37(38):5205-5220. PubMed ID: 29849119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
    Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
    Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.
    Gordeev SA; Bykova TV; Zubova SG; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
    Oncotarget; 2015 Dec; 6(42):44905-26. PubMed ID: 26636543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells.
    Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
    Anticancer Res; 2014 Oct; 34(10):5487-94. PubMed ID: 25275045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.
    Amico D; Barbui AM; Erba E; Rambaldi A; Introna M; Golay J
    Blood; 2003 Jun; 101(11):4589-97. PubMed ID: 12576328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of a dual mTORC1/2 inhibitor for the prevention of posterior capsule opacification: An in vitro study.
    Feng H; Yang Z; Bai X; Yang M; Fang Y; Zhang X; Guo Q; Ning H
    Int J Mol Med; 2018 Apr; 41(4):2099-2107. PubMed ID: 29344639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.
    Yang C; Huang X; Liu H; Xiao F; Wei J; You L; Qian W
    Oncotarget; 2017 Jun; 8(24):39185-39197. PubMed ID: 28402933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.
    Rutella S; Bonanno G; Procoli A; Mariotti A; Lucia MB; Contemi AM; Cauda R; Fianchi L; Scambia G; Pagano L; Leone G
    Exp Hematol; 2006 Jan; 34(1):54-65. PubMed ID: 16413391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
    Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
    Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in cellular model.
    Salama M; Elhussiny M; Magdy A; Omran AG; Alsayed A; Ashry R; Mohamed W
    Metab Brain Dis; 2018 Apr; 33(2):583-587. PubMed ID: 29080085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
    Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH
    Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin.
    Matsumoto T; Jimi S; Hara S; Takamatsu Y; Suzumiya J; Tamura K
    Leuk Lymphoma; 2012 Jul; 53(7):1399-405. PubMed ID: 22242821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
    Walter RB; Raden BW; Hong TC; Flowers DA; Bernstein ID; Linenberger ML
    Blood; 2003 Aug; 102(4):1466-73. PubMed ID: 12689934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells.
    Ono A; Oike R; Okuhashi Y; Takahashi Y; Itoh M; Nara N; Tohda S
    Anticancer Res; 2013 Mar; 33(3):809-13. PubMed ID: 23482748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
    Balaian L; Ball ED
    Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
    Rosen DB; Harrington KH; Cordeiro JA; Leung LY; Putta S; Lacayo N; Laszlo GS; Gudgeon CJ; Hogge DE; Hawtin RE; Cesano A; Walter RB
    PLoS One; 2013; 8(1):e53518. PubMed ID: 23320091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
    Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
    Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.